ImmunologybioRxiv
Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction
E. England, D. G. Rees, I. C. Scott…·E. S. Cohen
This paper describes tozorakimab, an anti-IL-33 antibody that inhibits both reduced and oxidized IL-33 signaling pathways to reduce inflammation and epithelial dysfunction.